Dermatology

This SDPA Summer Conference interview with Lisa Swanson, MD, highlights several notable treatment options for molluscum and hemangiomas.

At SDPA, Swanson highlighted a variety of key tips for clinicians, including strategies for treating hemangiomas and warts in children.

This Q&A interview highlights ways to counsel patients regarding the safety of various sunscreens, photoprotection, and UV radiation's impact on skin cancer.

This interview at the SDPA Summer Conference highlights the environment and climate change's impact on skin health and triggers of different conditions.

Stay updated with the latest healthcare breakthroughs, including data from ADA Scientific Sessions, a new CKM syndrome guideline, and more.

At the SDPA 2026 Summer Dermatology Conference, Mark Eliason, MD, and Mili Shum, MD, presented a joint session on treating chronic urticaria (CSU).

This SDPA interview with Steven Daveluy, MD, highlights integrative dermatology practices, acne strategies, and the value of supplements and dietary changes.

This discussion of integrative dermatology highlights ways to combine conventional medicine and complementary or alternative medicine.

In this SDPA Summer Dermatology Meeting interview, Zirwas speaks on treatment gaps for dermatologic conditions and off-label alternatives.

LATITUDE Atlas saw more than 35% of patients receiving zasocitinib 30 mg once daily reaching a PASI100 response at week 16, the primary endpoint.

This SDPA Summer 2026 talk highlights off-label treatment tips for dermatology clinicians in conditions such as alopecia areata, morphea, and different genital conditions.

This preview of the 2026 SDPA Summer Dermatology Conference highlights different sessions and interviews covered by the HCPLive team.

Eli Lilly announced FDA approval of a 250 mg every-8-week lebrikizumab maintenance regimen, supported by 32-week ADjoin extension data.

Natasha Mesinkovska, MD, PhD, speaks on the potential impact that an additional approved therapy like upadacitinib could have on younger patients with alopecia areata.

This interview on a possible upcoming therapeutic option for severe alopecia areata highlights information regarding upadacitinib (Rinvoq) and its potential.

The FDA marked bemotrizinol as first new active ingredient on the over-the-counter (OTC) sunscreen monograph since the 1990s.

This segment of the May episode of The Medical Sisterhood highlights key points regarding the impacts of role models on young patients in dermatology.

This segment of the latest Skin of Color Savvy episode highlights clinician viewpoints surrounding sun protection and skin cancer.

This Q&A interview highlights key takeaways regarding hidradenitis suppurativa, raising awareness for HS Awareness week, and the current treatment landscape.

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

New findings point to remaining gaps in AI diagnostic success for skin lesions compared with experienced clinicians in dermatology.

Vleugels discusses Part B findings on investigational IL-13 inhibitor zumilokibart (APG777) in adult patients with moderate-to-severe atopic dermatitis.

Krakowski and Torres-Zegarra discuss how to initiate the conversation about systemic therapy with families and review the guideline's drug hierarchy.

The experts review the guideline's approach to topicals for active atopic dermatitis, covering the appropriate use of topical corticosteroids and more.

This segment examines how the guideline navigates the tension between GRADE-based evidence thresholds and long-established clinical practices.